CTX — Captor Therapeutics SA Share Price
Last trade - 00:00- PLN147.20m
- PLN113.58m
- PLN15.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.28 | ||
| Price to Tang. Book | 2.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.76% | ||
| Return on Equity | -57.48% | ||
| Operating Margin | -246.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | n/a | 3.99 | 9.16 | 13.2 | 15.82 | 68.75 | 66.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 7th, 2018
- Public Since
- April 19th, 2021
- No. of Employees
- 91
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 4,673,104
- Address
- ul. Dunska 11, WROCLAW, 54-427
- Web
- https://www.captortherapeutics.pl/
- Phone
- Auditors
- Mazars Audyt Sp. z o.o.
Upcoming Events for CTX
Similar to CTX
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Genomed SA
Warsaw Stock Exchange
Genomtec SA
Warsaw Stock Exchange
Hyenergy SA
Warsaw Stock Exchange
FAQ
As of Today at 19:47 UTC, shares in Captor Therapeutics SA are trading at PLN31.50. This share price information is delayed by 15 minutes.
Shares in Captor Therapeutics SA last closed at PLN31.50 and the price had moved by -60.5% over the past 365 days. In terms of relative price strength the Captor Therapeutics SA share price has underperformed the FTSE Global All Cap Index by -61.49% over the past year.
The overall consensus recommendation for Captor Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCaptor Therapeutics SA does not currently pay a dividend.
Captor Therapeutics SA does not currently pay a dividend.
Captor Therapeutics SA does not currently pay a dividend.
To buy shares in Captor Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN31.50, shares in Captor Therapeutics SA had a market capitalisation of PLN147.20m.
Here are the trading details for Captor Therapeutics SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: CTX
Based on an overall assessment of its quality, value and momentum Captor Therapeutics SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Captor Therapeutics SA is PLN131.50. That is 317.46% above the last closing price of PLN31.50.
Analysts covering Captor Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of PLN0.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Captor Therapeutics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -54.39%.
As of the last closing price of PLN31.50, shares in Captor Therapeutics SA were trading -46.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Captor Therapeutics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN31.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Captor Therapeutics SA's directors